A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement?-Reference-Cited by-同舟云学术

A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement?

Published:2021-11-15 Issue:3 Volume:30 Page:2455-2465
ISSN:0941-4355
Container-title:Supportive Care in Cancer
language:en
Short-container-title:Support Care Cancer

Author:

Antonetti Paolo,Fargnoli Maria Concetta^ORCID,Porzio Giampiero,Salvatore Lisa,Filippi Roberto,Ghidini Michele,Nigro Olga,Gelsomino Fabio,Zurlo Ina Valeria,Dell’Aquila Emanuela,Lombardi Pasquale,Keränen Susana Roselló,Depetris Ilaria,Giampieri Riccardo,Morelli Cristina,De Tursi Michele,Di Pietro Francesca Romana,Zanaletti Nicoletta,Vitale Pasquale,Garajova Ingrid,Spinelli Gian Paolo,Zoratto Federica,Roberto Michela,Petrillo Angelica,Aimar Giacomo,Cortellini Alessio,Pensieri Maria Vittoria,Ficorella Corrado,Ferri Claudio,Parisi Alessandro

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

https://link.springer.com/content/pdf/10.1007/s00520-021-06652-5.pdf

Reference25 articles.

1. Van Cutsem E, Cervantes A, Adam R et al (2016) ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 27(8):1386–1422. https://doi.org/10.1093/annonc/mdw235

2. Linee guida AIOM TUMORI DEL COLON – Edizione 2020. Available at https://www.aiom.it/wp-content/uploads/2020/10/2020_LG_AIOM_Colon.pdf. Accessed 2021 July

3. Parisi A, Giampiero P, Cannita K et al (2021, ISSN 1533-0028) Clinicians’ attitude to doublet plus anti-EGFR versus triplet plus bevacizumab as first line treatment in left-sided RAS and BRAF wild-type metastatic colorectal cancer patients: a multicentre, “real-life”, case-control study. Clin Colorectal Cancer. https://doi.org/10.1016/j.clcc.2021.07.003

4. Grassadonia A, Di Marino P, Ficorella C et al (2019) Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: a retrospective multicenter study. J Cancer 10(24):5926–5934. https://doi.org/10.7150/jca.34550

5. Parisi A, Cortellini A, Venditti O et al (2021) Post-induction management in patients with left-sided RAS and BRAF wild- type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimens: a multicentre study. Front Oncol. https://doi.org/10.3389/fonc.2021.712053

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Skin Toxicity as a Predictor of Survival in Metastatic Colorectal Cancer Patients Treated with Anti-EGFR: Fact or Fallacy?;Cancers;2023-03-08

2. PRIDE syndrome associated with panitumumab treatment – case report and literature review;Dermatology Review;2023

3. Post-induction Strategies in Metastatic Colorectal Cancer Patients Treated With First-Line Anti-EGFR-Based Treatment: A Systematic Review and Meta-Analysis;Clinical Colorectal Cancer;2022-09